Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PETS's Cash to Debt is ranked higher than
99% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. PETS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PETS' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.91
PETS's Equity to Asset is ranked higher than
98% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. PETS: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
PETS' s Equity to Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.87 Max: 0.95
Current: 0.91
-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
99% of the 339 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.02 vs. PETS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PETS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 37.90
M-Score: -2.06
WACC vs ROIC
6.80%
66.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.33
PETS's Operating margin (%) is ranked higher than
95% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.86 vs. PETS: 14.33 )
Ranked among companies with meaningful Operating margin (%) only.
PETS' s Operating margin (%) Range Over the Past 10 Years
Min: 10.92  Med: 13.53 Max: 17.02
Current: 14.33
10.92
17.02
Net-margin (%) 9.10
PETS's Net-margin (%) is ranked higher than
94% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.66 vs. PETS: 9.10 )
Ranked among companies with meaningful Net-margin (%) only.
PETS' s Net-margin (%) Range Over the Past 10 Years
Min: 6.99  Med: 8.83 Max: 10.91
Current: 9.1
6.99
10.91
ROE (%) 26.10
PETS's ROE (%) is ranked higher than
92% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.52 vs. PETS: 26.10 )
Ranked among companies with meaningful ROE (%) only.
PETS' s ROE (%) Range Over the Past 10 Years
Min: 18.7  Med: 26.36 Max: 33.12
Current: 26.1
18.7
33.12
ROA (%) 23.51
PETS's ROA (%) is ranked higher than
99% of the 378 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.51 vs. PETS: 23.51 )
Ranked among companies with meaningful ROA (%) only.
PETS' s ROA (%) Range Over the Past 10 Years
Min: 16.88  Med: 23.74 Max: 29.73
Current: 23.51
16.88
29.73
ROC (Joel Greenblatt) (%) 109.68
PETS's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.58 vs. PETS: 109.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PETS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 91.28  Med: 114.3 Max: 194.27
Current: 109.68
91.28
194.27
Revenue Growth (3Y)(%) 0.60
PETS's Revenue Growth (3Y)(%) is ranked lower than
72% of the 320 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. PETS: 0.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PETS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.3  Med: 12.9 Max: 58
Current: 0.6
-0.3
58
EBITDA Growth (3Y)(%) 5.30
PETS's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.80 vs. PETS: 5.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PETS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.7  Med: 16.7 Max: 106.3
Current: 5.3
-8.7
106.3
EPS Growth (3Y)(%) 5.90
PETS's EPS Growth (3Y)(%) is ranked higher than
54% of the 258 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.00 vs. PETS: 5.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PETS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -9  Med: 14.9 Max: 104.1
Current: 5.9
-9
104.1
» PETS's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-01-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PETS Guru Trades in Q4 2015

Ken Fisher 187,116 sh (+9.14%)
John Buckingham 145,512 sh (+1.55%)
Jim Simons 1,704,320 sh (-3.91%)
Chuck Royce 301,500 sh (-14.22%)
Barrow, Hanley, Mewhinney & Strauss 154,452 sh (-31.01%)
» More
Q1 2016

PETS Guru Trades in Q1 2016

Joel Greenblatt 15,396 sh (New)
Chuck Royce 401,500 sh (+33.17%)
Ken Fisher 187,116 sh (unchged)
John Buckingham 142,406 sh (-2.13%)
Jim Simons 1,614,500 sh (-5.27%)
Barrow, Hanley, Mewhinney & Strauss 26,526 sh (-82.83%)
» More
Q2 2016

PETS Guru Trades in Q2 2016

Paul Tudor Jones 18,400 sh (New)
Jim Simons 1,662,315 sh (+2.96%)
Chuck Royce 401,500 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Joel Greenblatt Sold Out
Ken Fisher 148,049 sh (-20.88%)
John Buckingham 102,012 sh (-28.37%)
» More
Q3 2016

PETS Guru Trades in Q3 2016

Chuck Royce 401,500 sh (unchged)
Paul Tudor Jones Sold Out
John Buckingham 100,190 sh (-1.79%)
Jim Simons 1,567,915 sh (-5.68%)
Ken Fisher 115,453 sh (-22.02%)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:OTCBB:COCP, OTCPK:CWNM, NAS:CJJD, OTCPK:HEWA, NYSE:GNC, OTCPK:CLCGY, OTCPK:RADLY, NYSE:RAD, NAS:WBA » details
Traded in other countries:PQM.Germany,
PetMed Express Inc is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications and other health products for dogs, cats, and horses direct to the consumer.

PetMed Express Inc was incorporated in the state of Florida in January 1996. The Company is a nationwide pet pharmacy. It markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. It markets its products through national television, online, and direct mail/print advertising campaigns, which aim to increase the recognition of the "1-800-PetMeds" brand name and "PetMeds". It offers a selection of products for dogs and cats. Its current product line contains approximately 3,000 SKUs of the popular pet medications, health products, and supplies. These products include a majority of the brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution, and Rimadyl. The Company offers its products through three main sales channels: Internet through its website, telephone contact center through its toll-free number, and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards. It have designed its website and catalogs to provide a convenient, cost-effective, and informative shopping experience that encourages consumers to purchase products important for a pet's health and quality of life. Its customers are located throughout the United States, with approximately 50% of customers residing in California, Florida, New York, Texas, Pennsylvania, Virginia, North Carolina, and New Jersey. Its primary focus has been on retail customers. Its competitors consist of veterinarians, and online and traditional retailers. Its trademarks include PetMed Express and Design, 1888PetMeds and Design, 1-800-PetMeds and Design, 1-800-PetMeds, and PetMeds. The Company is subject to regulation by the State of Florida and is licensed as a community pharmacy by the Florida Board of Pharmacy.

Ratios

vs
industry
vs
history
P/E(ttm) 20.94
PETS's P/E(ttm) is ranked lower than
54% of the 311 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.85 vs. PETS: 20.94 )
Ranked among companies with meaningful P/E(ttm) only.
PETS' s P/E(ttm) Range Over the Past 10 Years
Min: 11.34  Med: 16.6 Max: 40.4
Current: 20.94
11.34
40.4
Forward P/E 20.75
PETS's Forward P/E is ranked lower than
77% of the 61 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.33 vs. PETS: 20.75 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.94
PETS's PE(NRI) is ranked lower than
53% of the 309 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.22 vs. PETS: 20.94 )
Ranked among companies with meaningful PE(NRI) only.
PETS' s PE(NRI) Range Over the Past 10 Years
Min: 11.34  Med: 16.6 Max: 40.4
Current: 20.94
11.34
40.4
Price/Owner Earnings (ttm) 16.64
PETS's Price/Owner Earnings (ttm) is ranked higher than
60% of the 202 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.62 vs. PETS: 16.64 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PETS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.6  Med: 18.79 Max: 51.39
Current: 16.64
8.6
51.39
P/B 5.23
PETS's P/B is ranked lower than
89% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.71 vs. PETS: 5.23 )
Ranked among companies with meaningful P/B only.
PETS' s P/B Range Over the Past 10 Years
Min: 2.33  Med: 4.33 Max: 13.25
Current: 5.23
2.33
13.25
P/S 1.90
PETS's P/S is ranked lower than
90% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.45 vs. PETS: 1.90 )
Ranked among companies with meaningful P/S only.
PETS' s P/S Range Over the Past 10 Years
Min: 0.84  Med: 1.54 Max: 3.5
Current: 1.9
0.84
3.5
PFCF 51.05
PETS's PFCF is ranked lower than
87% of the 153 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.26 vs. PETS: 51.05 )
Ranked among companies with meaningful PFCF only.
PETS' s PFCF Range Over the Past 10 Years
Min: 7.89  Med: 18.54 Max: 609.71
Current: 51.05
7.89
609.71
POCF 13.10
PETS's POCF is ranked lower than
66% of the 198 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.68 vs. PETS: 13.10 )
Ranked among companies with meaningful POCF only.
PETS' s POCF Range Over the Past 10 Years
Min: 7.7  Med: 16.36 Max: 46.6
Current: 13.1
7.7
46.6
EV-to-EBIT 11.89
PETS's EV-to-EBIT is ranked higher than
66% of the 318 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.82 vs. PETS: 11.89 )
Ranked among companies with meaningful EV-to-EBIT only.
PETS' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.7  Med: 9.2 Max: 25.5
Current: 11.89
4.7
25.5
EV-to-EBITDA 11.62
PETS's EV-to-EBITDA is ranked lower than
52% of the 330 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.41 vs. PETS: 11.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
PETS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 8.95 Max: 24.8
Current: 11.62
4.5
24.8
PEG 12.29
PETS's PEG is ranked lower than
90% of the 163 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. PETS: 12.29 )
Ranked among companies with meaningful PEG only.
PETS' s PEG Range Over the Past 10 Years
Min: 0.33  Med: 0.69 Max: 94
Current: 12.29
0.33
94
Shiller P/E 22.82
PETS's Shiller P/E is ranked lower than
51% of the 81 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.80 vs. PETS: 22.82 )
Ranked among companies with meaningful Shiller P/E only.
PETS' s Shiller P/E Range Over the Past 10 Years
Min: 13.11  Med: 17.75 Max: 36.56
Current: 22.82
13.11
36.56
Current Ratio 8.71
PETS's Current Ratio is ranked higher than
98% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.22 vs. PETS: 8.71 )
Ranked among companies with meaningful Current Ratio only.
PETS' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 7.09 Max: 17.46
Current: 8.71
0.29
17.46
Quick Ratio 6.98
PETS's Quick Ratio is ranked higher than
98% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.72 vs. PETS: 6.98 )
Ranked among companies with meaningful Quick Ratio only.
PETS' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 4.63 Max: 14.61
Current: 6.98
0.11
14.61
Days Inventory 49.07
PETS's Days Inventory is ranked lower than
61% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.30 vs. PETS: 49.07 )
Ranked among companies with meaningful Days Inventory only.
PETS' s Days Inventory Range Over the Past 10 Years
Min: 49.07  Med: 63.9 Max: 78.88
Current: 49.07
49.07
78.88
Days Sales Outstanding 2.09
PETS's Days Sales Outstanding is ranked higher than
86% of the 278 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.97 vs. PETS: 2.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
PETS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.09  Med: 3.06 Max: 4.79
Current: 2.09
2.09
4.79
Days Payable 13.63
PETS's Days Payable is ranked lower than
92% of the 267 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 45.81 vs. PETS: 13.63 )
Ranked among companies with meaningful Days Payable only.
PETS' s Days Payable Range Over the Past 10 Years
Min: 11.53  Med: 13.73 Max: 21.9
Current: 13.63
11.53
21.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.34
PETS's Dividend Yield is ranked higher than
79% of the 489 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.77 vs. PETS: 3.34 )
Ranked among companies with meaningful Dividend Yield only.
PETS' s Dividend Yield Range Over the Past 10 Years
Min: 0.51  Med: 4.17 Max: 5.85
Current: 3.34
0.51
5.85
Dividend Payout 0.69
PETS's Dividend Payout is ranked lower than
52% of the 290 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.32 vs. PETS: 0.69 )
Ranked among companies with meaningful Dividend Payout only.
PETS' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.67 Max: 1.21
Current: 0.69
0.31
1.21
Dividend Growth (3y) 6.30
PETS's Dividend Growth (3y) is ranked higher than
50% of the 183 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.40 vs. PETS: 6.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
PETS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 26
Current: 6.3
0
26
Forward Dividend Yield 3.36
PETS's Forward Dividend Yield is ranked higher than
76% of the 470 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.13 vs. PETS: 3.36 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.09
PETS's Yield on cost (5-Year) is ranked higher than
76% of the 495 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.03 vs. PETS: 5.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PETS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.78  Med: 6.36 Max: 8.92
Current: 5.09
0.78
8.92
3-Year Average Share Buyback Ratio -0.60
PETS's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 197 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. PETS: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PETS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -0.15 Max: 4.5
Current: -0.6
-45.6
4.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.62
PETS's Price/Net Cash is ranked lower than
54% of the 26 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.36 vs. PETS: 10.62 )
Ranked among companies with meaningful Price/Net Cash only.
PETS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.77  Med: 8.62 Max: 34.59
Current: 10.62
3.77
34.59
Price/Net Current Asset Value 6.96
PETS's Price/Net Current Asset Value is ranked lower than
55% of the 122 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. PETS: 6.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PETS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.56  Med: 5.7 Max: 40
Current: 6.96
2.56
40
Price/Tangible Book 5.28
PETS's Price/Tangible Book is ranked lower than
81% of the 326 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.00 vs. PETS: 5.28 )
Ranked among companies with meaningful Price/Tangible Book only.
PETS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.37  Med: 4.94 Max: 243.33
Current: 5.28
2.37
243.33
Price/Projected FCF 1.94
PETS's Price/Projected FCF is ranked lower than
67% of the 215 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.37 vs. PETS: 1.94 )
Ranked among companies with meaningful Price/Projected FCF only.
PETS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.3 Max: 7.7
Current: 1.94
0.54
7.7
Price/Median PS Value 1.24
PETS's Price/Median PS Value is ranked lower than
66% of the 310 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. PETS: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
PETS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 0.99 Max: 2.02
Current: 1.24
0.3
2.02
Price/Peter Lynch Fair Value 3.90
PETS's Price/Peter Lynch Fair Value is ranked lower than
89% of the 81 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.66 vs. PETS: 3.90 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PETS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.55  Med: 0.79 Max: 3.9
Current: 3.9
0.55
3.9
Price/Graham Number 2.22
PETS's Price/Graham Number is ranked lower than
71% of the 259 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.50 vs. PETS: 2.22 )
Ranked among companies with meaningful Price/Graham Number only.
PETS' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 1.95 Max: 5.88
Current: 2.22
1.09
5.88
Earnings Yield (Greenblatt) (%) 8.40
PETS's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.10 vs. PETS: 8.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PETS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 10.9 Max: 21.2
Current: 8.4
3.9
21.2
Forward Rate of Return (Yacktman) (%) 9.19
PETS's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 228 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.66 vs. PETS: 9.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PETS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.8  Med: 15.15 Max: 65.7
Current: 9.19
0.8
65.7

More Statistics

Revenue (TTM) (Mil) $239.6
EPS (TTM) $ 1.07
Beta0.59
Short Percentage of Float18.42%
52-Week Range $15.73 - 22.75
Shares Outstanding (Mil)20.53

Analyst Estimate

Mar17 Mar18
Revenue (Mil $)
EPS ($) 1.02 1.09
EPS w/o NRI ($) 1.02 1.09
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:PETS

Headlines

Articles On GuruFocus.com
Own These Four Dividend Stocks Instead of a Condo Nov 04 2015 
10 High-Yielding Small Caps For A Portfolio Return Boost Apr 23 2015 
Bob Olstein Says Forget Amazon, Buy PetSmart, Teradata Jun 13 2014 
PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
4 Cash Gushing, Undervalued Small Cap Stocks With Zero Debt Apr 08 2014 
4 Biggest Dividend Challengers with Low Debt and Nice Initial Yields Aug 28 2013 
12 Dividend Stocks Sending More Cash to Shareholders Aug 05 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
PetMed Express - Debt-Free with Attractive Dividend Yield Nov 26 2012 
Horatio Gulash: Analyzing Advertising Expense Jun 11 2012 

More From Other Websites
PetSmart's Recent Acquisition Shows How Valuations Have Changed Nov 14 2016
PETMED EXPRESS INC Financials Nov 04 2016
PETMED EXPRESS INC Files SEC form 10-Q, Quarterly Report Nov 01 2016
ETF’s with exposure to PetMed Express, Inc. : October 28, 2016 Oct 28 2016
PETMED EXPRESS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 26 2016
PetMed Express, Inc. :PETS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 26, 2016 Oct 26 2016
PetMed Express, Inc. breached its 50 day moving average in a Bearish Manner : PETS-US : October 25,... Oct 25 2016
PetMed (PETS) Earnings Miss, Revenues Top Estimates in Q2 Oct 25 2016
Edited Transcript of PETS earnings conference call or presentation 24-Oct-16 12:30pm GMT Oct 24 2016
PetMed misses 2Q profit forecasts Oct 24 2016
PetMed misses 2Q profit forecasts Oct 24 2016
PetMed Express D/B/A 1-800-PetMeds Announces Its Second Quarter Financial Results and Its $0.19 Per... Oct 24 2016
Q2 2016 Petmed Express Inc Earnings Release - 08:00 am ET Oct 24 2016
Trifecta Stocks: A Big Week on Tap for the Portfolio Oct 23 2016
PETMED EXPRESS INC Files SEC form 8-K, Other Events Oct 18 2016
PetMed Express D/B/A 1-800-PetMeds to Announce Its Second Quarter Financial Results on October 24,... Oct 17 2016
PetMed Express, Inc. : PETS-US: Dividend Analysis : August 08th, 2016 (record date) : By the numbers... Oct 13 2016
PetMed Express, Inc. breached its 50 day moving average in a Bearish Manner : PETS-US : October 12,... Oct 12 2016
Top 5 Pharma Retail : October 6, 2016 Oct 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)